AR069682A1 - Tratamiento de melanoma con peptidos timosina alfa en combinacion con anticuerpos contra antigeno 4 asociado con linfocitos t citotoxicos (ctla4) - Google Patents
Tratamiento de melanoma con peptidos timosina alfa en combinacion con anticuerpos contra antigeno 4 asociado con linfocitos t citotoxicos (ctla4)Info
- Publication number
- AR069682A1 AR069682A1 ARP080105419A ARP080105419A AR069682A1 AR 069682 A1 AR069682 A1 AR 069682A1 AR P080105419 A ARP080105419 A AR P080105419A AR P080105419 A ARP080105419 A AR P080105419A AR 069682 A1 AR069682 A1 AR 069682A1
- Authority
- AR
- Argentina
- Prior art keywords
- combination
- melanoma
- alpha
- ctla4
- antibodies against
- Prior art date
Links
- 201000001441 melanoma Diseases 0.000 title abstract 4
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 title abstract 3
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 title abstract 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 title abstract 2
- 101710135378 pH 6 antigen Proteins 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 238000000034 method Methods 0.000 abstract 4
- 238000011269 treatment regimen Methods 0.000 abstract 3
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 abstract 2
- 108010046075 Thymosin Proteins 0.000 abstract 2
- 239000002295 alkylating antineoplastic agent Substances 0.000 abstract 2
- 229960005386 ipilimumab Drugs 0.000 abstract 2
- 206010027476 Metastases Diseases 0.000 abstract 1
- 108010078233 Thymalfasin Proteins 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 229960003901 dacarbazine Drugs 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1310107P | 2007-12-12 | 2007-12-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR069682A1 true AR069682A1 (es) | 2010-02-10 |
Family
ID=40755783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080105419A AR069682A1 (es) | 2007-12-12 | 2008-12-12 | Tratamiento de melanoma con peptidos timosina alfa en combinacion con anticuerpos contra antigeno 4 asociado con linfocitos t citotoxicos (ctla4) |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20100330093A1 (enExample) |
| EP (1) | EP2240195A4 (enExample) |
| JP (1) | JP2011506436A (enExample) |
| CN (1) | CN101896190A (enExample) |
| AR (1) | AR069682A1 (enExample) |
| AU (1) | AU2008335840A1 (enExample) |
| CA (1) | CA2709027A1 (enExample) |
| WO (1) | WO2009075813A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130296223A1 (en) * | 2012-03-30 | 2013-11-07 | Sciclone Pharmaceuticals, Inc. | Use of thymosin alpha for the treatment of sepsis |
| WO2013177102A2 (en) * | 2012-05-21 | 2013-11-28 | Felder Mitchell S | Treatment of cancer by manipulating the immune system |
| EP3943101A1 (en) | 2014-10-21 | 2022-01-26 | SciClone Pharmaceuticals International Ltd. | Treatment of cancer with immune stimulator alpha thymosin peptide |
| US10806787B2 (en) | 2015-02-16 | 2020-10-20 | Pharma Foods International Co., Ltd. | Anticancer agents or antimetastatic agents using FSTL1 and combination drug thereof |
| JP7069032B2 (ja) | 2016-03-24 | 2022-05-17 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | がん免疫治療における胃腸の免疫関連有害事象の治療方法 |
| TW201735949A (zh) | 2016-03-24 | 2017-10-16 | 千禧製藥公司 | 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法 |
| CN109793891A (zh) * | 2017-11-17 | 2019-05-24 | 韩震 | 多肽化合物在制备提高治疗性抗体疗效的佐剂中的应用与组合物及其制备方法 |
| IT201900016310A1 (it) * | 2019-09-13 | 2021-03-13 | Luigina Romani | Timosina alfa 1 per l’uso nella prevenzione e nel trattamento degli effetti avversi immunitari correlati agli inibitori di checkpoint immunitari. |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2604845A1 (de) * | 1976-02-07 | 1977-08-18 | Knoll Ag | Neue piperazinderivate |
| EP2633866A3 (en) * | 2003-10-17 | 2013-12-18 | Novo Nordisk A/S | Combination therapy |
-
2008
- 2008-12-08 JP JP2010537941A patent/JP2011506436A/ja not_active Withdrawn
- 2008-12-08 AU AU2008335840A patent/AU2008335840A1/en not_active Abandoned
- 2008-12-08 WO PCT/US2008/013480 patent/WO2009075813A1/en not_active Ceased
- 2008-12-08 CA CA2709027A patent/CA2709027A1/en not_active Abandoned
- 2008-12-08 US US12/747,817 patent/US20100330093A1/en not_active Abandoned
- 2008-12-08 CN CN2008801206945A patent/CN101896190A/zh active Pending
- 2008-12-08 EP EP08859253A patent/EP2240195A4/en not_active Withdrawn
- 2008-12-12 AR ARP080105419A patent/AR069682A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20100330093A1 (en) | 2010-12-30 |
| CA2709027A1 (en) | 2009-06-18 |
| WO2009075813A1 (en) | 2009-06-18 |
| EP2240195A1 (en) | 2010-10-20 |
| CN101896190A (zh) | 2010-11-24 |
| EP2240195A4 (en) | 2011-12-21 |
| AU2008335840A1 (en) | 2009-06-18 |
| JP2011506436A (ja) | 2011-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR069682A1 (es) | Tratamiento de melanoma con peptidos timosina alfa en combinacion con anticuerpos contra antigeno 4 asociado con linfocitos t citotoxicos (ctla4) | |
| AR053651A1 (es) | Tratamiento combinado de anticuerpo antictla4 r inhibidor de aromatasa para el cancer de mama | |
| AR060306A1 (es) | Terapia de combinacion de anticuerpos contra ctla4 | |
| EP1504778A3 (en) | Implantable pump for the treatment of obesity | |
| ECSP056076A (es) | Sistema de suministro para droga y terapia celular | |
| AR054237A1 (es) | Terapia de combinacion de anticuerpo antictla4 e indolinona para el tratamiento del cancer | |
| AU2000277238A1 (en) | Non-mammalian gnrh analogs and uses thereof in tumor cell growth regulation and cancer therapy | |
| DE60327843D1 (de) | Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid | |
| ES2154299T3 (es) | Metodos para la regulacion de la motilidad gastrointestinal. | |
| MY199821A (en) | Modified lipidated relaxin b chain peptides and their therapeutic use | |
| JP2011506436A5 (enExample) | ||
| AR069767A1 (es) | Tratamiento del melanoma con peptidos timosina alfa en combinacion con activador de apoptosis de choque termico entineoplastico (hsaa) | |
| CY1110078T1 (el) | Παρασκευασματα με ιωδιουχο ποβιδονη για την αγωγη τραυματων | |
| TR200101633T2 (tr) | Farmasötik bileşim | |
| BR0213821A (pt) | Conjugados de polìmero/peptìdeo timosina alfa 1 | |
| BR0213823A (pt) | Método de administração de um peptìdeo timosina alfa 1 | |
| AR023185A1 (es) | Tratamiento de cancer mejorado con temozolomida | |
| DE50212918D1 (de) | Polypeptid, dessen konjugat doxorubicin enthält, uetzung | |
| AR069769A1 (es) | Tratamiento del melanoma con peptidos de timosina alfa en combinacion con un inhibidor de quinasas | |
| RU2006119263A (ru) | Способ лечения больных розацеа | |
| HK1148938A (en) | Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic t lymphocyte-associated antigen 4 (ctla4) | |
| JP2020524167A5 (enExample) | ||
| TR200000728T2 (tr) | Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı. | |
| Jang et al. | Hepatoprotective effects of catechin in carbon tetrachloride-induced hepatic damage in rats | |
| TW200626172A (en) | Treatment of HIV infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |